Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation

Arnljot Tveit, Ingebjørg Seljeflot, Pal Smith, Harald Arnesen, Jesper Hastrup Svendsen

    2 Citationer (Scopus)

    Abstrakt

    High levels of the novel inflammatory marker YKL-40 have been demonstrated in inflammatory environments and in remodeling of the extracellular matrix. Both are key components in atrial wall remodeling in atrial fibrillation (AF). We studied the relation between rhythm outcome after electrical cardioversion (ECV) for persistent AF and serum levels of YKL-40. A secondary point of interest was a potential effect of the angiotensin receptor blocker candesartan on YKL-40 levels. In the Candesartan in the Prevention of Relapsing Atrial Fibrillation (CAPRAF) study, 171 patients with persistent AF were randomized to receive candesartan 8mg once daily or placebo for 3-6 weeks before ECV and candesartan 16mg once daily or placebo for 6 months after ECV. Serum levels of YKL-40 were measured in fasting blood samples collected at baseline and at end of the study. Mean age was 64±11 years, and 39 (22.8%) were women. Sinus rhythm was maintained for 6 months after ECV in 41 (23.9%). Baseline levels of YKL-40 were significantly correlated to age (Spearmans rho; rs=0.442; p
    OriginalsprogEngelsk
    TidsskriftImmunobiology
    Vol/bind218
    Udgave nummer10
    Sider (fra-til)1256-60
    Antal sider5
    ISSN0171-2985
    DOI
    StatusUdgivet - okt. 2013

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation'. Sammen danner de et unikt fingeraftryk.

    Citationsformater